SGLT2 inhibitor (SGLT2i) exerts not only on enhancement of glucose excretion but also on improvement of serum lipid profile via increase in lipid utilization as an energy source instead of glucose. That is, SGLT2i might affect the lipid storage. In the present study, we evaluated the effects of dapagliflozin (DAPA) on weight and fatty acid contents of adipose tissues.

At 8 weeks of age, male rats were divided into four groups: (a) NC (n=6) fed on a standard laboratory chow (LC); (b) NC+DAPA (n=6) on the LC with 1 mg/kg/day DAPA administration; (c) HFD (n=6) on a high-fat diet (HF); (d) HFD+DAPA (n=6) on the HF with 1 mg/kg/day DAPA administration. After 7 weeks, we weighed epididymal (EPI), mesenteric (MES), retroperitoneal (RET), and inguinal subcutaneous (SUB) adipose tissues, and measured 21 adipose fatty-acid contents (μmol/g BW).

As a result, adipose tissue weight in the examined four sites in HFD rats were significantly higher (P<0.01) than those, respectively, in NC rats. No significant differences were observed in weights of any adipose tissues or in their contents of fatty acids between the NC and NC+DAPA rats. In contrast, MES weight in HFD+DAPA rats was significantly lower (P<0.05) than that in the HFD rats. Contents of 1, 3, 2 and 1 saturated fatty acids (SFAs) in EPI, MES, RET and SUB, respectively, in the HFD+DAPA rats were significantly lower (P<0.05) than those, respectively, in the HFD rats. Contents of 3 and 2 monounsaturated fatty acids in MES and SUB, respectively, and contents of 2 and 1 polyunsaturated fatty acids in MES and RET, respectively, in the HFD+DAPA rats were significantly lower (P<0.05) than those, respectively, in the HFD rats.

These results suggest that DAPA could reduce some SFAs in any adipose tissues in HF-fed rats, but not in LC-fed rats. The reduction might sometimes arise without concomitant decrease in tissue weight. In addition, DAPA might suppress accumulation of a wide range of fatty acids in MES of HF-fed rats in particular, probably due to their consumption.


D. Sato: None. J. Amarume: None. M. Yano: None. Y. Umehara: None. M. Kusunoki: Other Relationship; Self; Kaken Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd. Z. Feng: None. T. Nakamura: Research Support; Self; AstraZeneca K.K., Ono Pharmaceutical Co., Ltd.


Ono Pharmaceutical Co., Ltd.; AstraZeneca K.K.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at